BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Efficacy and Safety Oral Contraceptive Study
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1113
- Registration Number
- NCT00185484
Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch
Phase 3
Completed
- Conditions
- Hot Flashes
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 165
- Registration Number
- NCT00185237
Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries
Phase 3
Completed
- Conditions
- Peripheral Vascular Disease
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 365
- Registration Number
- NCT00185276
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Phase 2
Completed
- Conditions
- Melanoma
- Interventions
- Drug: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 28
- Registration Number
- NCT00185302
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.
Phase 2
Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: SH T00268CDrug: PTK787/ ZK 222584
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 112
- Registration Number
- NCT00160043
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non Small Cell Lung
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 128
- Registration Number
- NCT00160069
Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2009-01-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT00119639
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 189
- Registration Number
- NCT00117637
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Phase 2
Completed
- Conditions
- CancerMelanoma
- Interventions
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 101
- Registration Number
- NCT00110994
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2567
- Registration Number
- NCT00111020
© Copyright 2025. All Rights Reserved by MedPath